As a result, after the cancer cells were quickly killed by alpha particles from 225Ac, the radiation from the actinium and its daughters might induce new mutations. To solve this problem, 225Ac was bound to a chelating agent, such as citrate, ethylenediaminetetraacetic acid (EDTA) or diethylene triamine pentaacetic acid (DTPA). This reduced actinium accumulation in the bones, but the excretion from the body remained slow.
Consequently, following the rapid eradication of cancer cells by alpha particles from 225Ac, the radiation emitted by the actinium and its progeny could potentially cause new mutations. To address this issue, 225Ac was attached to a chelating agent, such as citrate, ethylenediaminetetraacetic acid (EDTA), or diethylene triamine pentaacetic acid (DTPA). This minimized actinium accumulation in the bones, but the elimination from the body continued to be sluggish.